One big East Coast pharmaceutical firm abandoned work on a hepatitis C drug this week, while another shuttered a young company that had cost it $720 million to acquire. But new ideas continue to burst forth, and investors pitched in $20 million for another hopeful startup.
The Connecticut company that figured out how to make a recombinant flu vaccine is now trying to invent a marketing strategy for it. And in New Jersey, one of the biggest sources of marketing data for drug companies snapped up a startup that helps organize all that information.
{iframe}http://www.xconomy.com/boston/2013/03/15/east-coast-life-sciences-roundup-gsk-protein-sciences-ims-health/{/iframe}